NPM1 and acute promyelocytic leukemia: These patients seem to have a better outcome than AML-NPM1 mutated without APL-like features, with significantly longer relapse-free survival (median 64 vs. 9 months) and overall survival (median 81 vs. 20 months) in those who achieved CR (137).